Under fire

Broadsides aimed at the synthetic securitisation market, and by implication, the credit derivatives market by the chairman of the FSA have left bankers fuming. But while the asides from the UK regulator may have shown a lack of understanding of the big picture, the issues surrounding the rise of insurance investment banking should not be taken lightly. Mark Pelham reports.

Synthetic securitisations, and by implication the credit derivatives market that underpins them, have recently come under scrutiny and in some cases heavy criticism from regulators, particularly over their use in transferring credit risk from the banking to the insurance sectors. Although there is some basis for concern, with insurance companies’ results suffering because of their synthetic holdings, bankers in the credit derivatives market say that is not the whole story. In fact, they believe

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Credit risk & modelling – Special report 2021

This Risk special report provides an insight on the challenges facing banks in measuring and mitigating credit risk in the current environment, and the strategies they are deploying to adapt to a more stringent regulatory approach.

The wild world of credit models

The Covid-19 pandemic has induced a kind of schizophrenia in loan-loss models. When the pandemic hit, banks overprovisioned for credit losses on the assumption that the economy would head south. But when government stimulus packages put wads of cash in…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here